Low Microsomal Epoxide Hydrolase Expression is Associated with Bladder Carcinogenesis and Recurrence

  • Zhang, Zhe (Department of Urology, The First Hospital of China Medical University) ;
  • Yu, Xiu-Yue (Department of Urology, The First Hospital of China Medical University) ;
  • Zhang, Guo-Jun (Department of Hematology, Shengjing Hospital of China Medical University) ;
  • Guo, Kun-Feng (Department of Urology, The First Hospital of China Medical University) ;
  • Kong, Chui-Ze (Department of Urology, The First Hospital of China Medical University)
  • Published : 2012.02.29


Microsomal epoxide hydrolase (mEH) plays a significant role in the metabolism of numerous xenobiotics and is associated with several forms of cancer. Here, we investigated the role of mEH expression in bladder carcinogenesis, subsequent progression and recurrence. The expression of mEH was analyzed by Western blot in 50 bladder urothelial carcinoma and 20 normal epithelial tissues. There was a significantly higher mEH expression in the normal epithelium (P<0.05) and mEH expression was lower in high stage than in low stage tumors (P<0.05). Further, immunohistochmistry in 106 bladder urothelial carcinoma demonstrated mEH expression to be negatively correlated with histological grade, pT stage and recurrence (P<0.05). These findings suggest the important role of mEH in bladder carcinogenesis, cancer development and recurrence, providing support for efforts to develop mEH-based gene therapy.


mEH;bladder carcinoma;histopathological grade;clinical stage;recurrence


  1. Abdel-Rahman, S.Z., Ammenheuser, MM, Omiecinski, CJ, et al (2005). Variability in human sensitivity to 1,3-butadiene: influence of polymorphisms in the 5'-flanking region of the microsomal epoxide hydrolase gene (EPHX1). Toxicol Sci, 85, 624-31.
  2. Boffetta, P, Nyberg, F (2003). Contribution of environmental factors to cancer risk. Br. Med. Bull, 68, 71-94.
  3. Brockmoller, J, Kaiser, R, Kerb, R, et al (1996). Polymorphic enzymes of xenobiotic metabolism as modulators of acquired P53 mutations in bladder cancer. Pharmacogenetics, 6, 535-45.
  4. Crockett, DG, Wagner, DG, Holmang, S, et al (2011). Upper urinary tract carcinoma in Lynch syndrome cases. J Urol, 185, 1627-30.
  5. Daneshmand S, Stein, JP, Lesser, T, et al (2004). Prognosis of seminal vesicle involvement by transitional cell carcinoma of the bladder. J Urol, 172, 81-4.
  6. Engel S, Jensen, PR, Fenical, W (2002). Chemical ecology of marine microbial defense. J Chem Ecol, 28, 1971-85.
  7. Erkisi Z, Yaylim-Eraltan I, Turna A, et al (2010). Polymorphisms in the microsomal epoxide hydrolase gene: role in lung cancer susceptibility and prognosis. Tumori, 96, 756-63.
  8. Garcia-Closas M, Malats N, Silverman, D, et al (2005). NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet, 366, 649-59.
  9. Goode EL, White KL, Vierkant RA, et al (2011). Xenobiotic- Metabolizing gene polymorphisms and ovarian cancer risk. Mol. Carcinog, 50, 397-402.
  10. Gupta R, Paner GP, Amin MB (2008). Neoplasms of the upper urinary tract: a review with focus on urothelial carcinoma of the pelvicalyceal system and aspects related to its diagnosis and reporting. Adv. Anat. Pathol, 15, 127-39.
  11. Harrison DJ, Hubbard AL, MacMillan J, et al (1999). Microsomal epoxide hydrolase gene polymorphism and susceptibility to colon cancer. Br J Cancer, 79, 168-71.
  12. Hassett C, Aicher L, Sidhu JS, et al (1994). Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet, 3, 421-8.
  13. Hsu LI, Chiu AW, Huan SK, et al (2008). SNPs of GSTM1, T1, P1, epoxide hydrolase and DNA repair enzyme XRCC1 and risk of urinary transitional cell carcinoma in southwestern Taiwan.Toxicol Appl Pharmacol, 228, 144-55.
  14. Ihsan R, Chattopadhyay I, Phukan R, et al (2010). Role of epoxide hydrolase 1 gene polymorphisms in esophageal cancer in a high-risk area in India. J Gastroenterol Hepatol, 25, 1456-62.
  15. Kang S, Duan LH, Li Y, et al (2004). [Relation Between microsomal epoxide hydrolase polymorphism and susceptibility to ovarian epithelial cancer]. Zhonghua Fu Chan Ke Za Zhi, 39, 556-7.
  16. Khedhaier A, Hassen E, Bouaouina N, et al (2008). Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma. BMC Cancer, 8, 109.
  17. Kiran M, Chawla YK, Jain M, et al (2009a). Haplotypes of microsomal epoxide hydrolase and x-ray crosscomplementing group 1 genes in Indian hepatocellular carcinoma patients. DNA Cell Biol, 28, 573-77.
  18. Kyrgidis A, Tzellos TG, Vahtsevanos K, et al (2010). New concepts for basal cell carcinoma. Demographic, clinical, histological risk factors, and biomarkers. A systematic review of evidence regarding risk for tumor development, susceptibility for second primary and recurrence. J Surg Res, 159, 545-56.
  19. Lacko M, Oude OMB, Peters WH et al (2009). Genetic polymorphisms of smoking-related carcinogen detoxifying enzymes and head and neck cancer susceptibility. Anticancer Res, 29, 753-761.
  20. Li X, Hu Z, Qu X, et al (2011). Putative EPHX1 enzyme activity is related with risk of lung and upper aerodigestive tract cancers: a comprehensive meta-analysis. PLoS One, 6, e14749.
  21. Lotan Y, Svatek RS, Malats N (2008). Screening for bladder cancer: a perspective. World J Urol, 26, 13-8.
  22. Mukherjee JJ, Kumar S, Gocinski R, et al (2011). Phenolic fraction of tobacco smoke inhibits BPDE-induced apoptosis response and potentiates cell transformation: role of attenuation of p53 response. Chem. Res. Toxicol, 24, 698- 705.
  23. Nock NL, Tang D, Rundle A, et al (2007). Associations between smoking, polymorphisms in polycyclic aromatic hydrocarbon (PAH) metabolism and conjugation genes and PAH-DNA adducts in prostate tumors differ by race.Cancer Epidemiol. Biomarkers Prev, 16, 1236-45.
  24. Okkels H, Sigsgaard T, Wolf H, et al (1997). Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol. Biomarkers Prev, 6, 225-31.
  25. Pande M, Amos CI, Osterwisch DR, et al (2008). Genetic variation in genes for the xenobiotic-metabolizing enzymes CYP1A1, EPHX1, GSTM1, GSTT1, and GSTP1 and susceptibility to colorectal cancer in Lynch syndrome.Cancer Epidemiol. Biomarkers Prev, 17, 2393-401.
  26. Rosenberger A, Illig T, Korb K, et al (2008). Do genetic factors protect for early onset lung cancer? A case control study before the age of 50 years. BMC Cancer, 8, 60.
  27. Rothman N, Garcia-Closas M, Chatterjee N, et al (2010). A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat. Genet, 42, 978-84.
  28. Shou J, Gong Y, Wu D (1996). Oncogenic transformation of Syrian hamster embryo cells by 5.3-MeV alpha particles and a tumor promoter phorbol ester.Chin. Med Sci J, 11, 195-9.

Cited by

  1. Effect of Bcl-2 on Apoptosis and Transcription Factor NF-κB Activation Induced by Adriamycin in Bladder Carcinoma BIU87 Cells vol.14, pp.4, 2013,
  2. Extrahepatic metabolism at the body's internal–external interfaces vol.46, pp.3, 2014,